Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species
High PTPN11 expression is associated with Pancreatic cancer.
SHP-2 acts together with PI3K (show PIK3CA ELISA Kits)/AKT (show AKT1 ELISA Kits) to regulate a ZEB1 (show ZEB1 ELISA Kits)-miR (show MLXIP ELISA Kits)-200 feedback loop in PDGFRalpha-driven gliomas.
Results provide evidence that repression of SHP-1 (show PTPN6 ELISA Kits), SHP-2 and SOCS-1 (show SOCS1 ELISA Kits) gene expression in patient plasma cells supports the constitutive activation of the JAK (show JAK3 ELISA Kits)/STAT3 (show STAT3 ELISA Kits) pathway and probably leads to higher degrees of bone marrow invasion.
The data presented in the current study reveal that intestinal serotonin transporter (SERT (show SLC6A4 ELISA Kits)) is a target of the tyrosine phosphatase SHP2 and show a novel mechanism by which a common diarrheagenic pathogen, EPEC, activates cellular SHP2 to inhibit SERT (show SLC6A4 ELISA Kits) function.
The effects of SHP2 overexpression and inhibition on fibroblast response to profibrotic stimuli were analyzed in in primary human fibroblasts. SHP2 was down-regulated and lung fibroblasts obtained from patients with IPF, revealing SHP2 was absent within fibroblastic foci sufficient to induce fibroblast-to-myofibroblast differentiation in primary human lung fibroblasts, resulting in reduced cell survival.
PTPN11 variant was identified in a case with a lethal presentation of Noonan syndrome.
our results provide strong evidence that CD244 (show CD244 ELISA Kits) co-operates with c-Kit (show KIT ELISA Kits) to regulate leukemogenesis through SHP-2/p27 (show PAK2 ELISA Kits) signaling.
SHP2, SOCS3 (show SOCS3 ELISA Kits) and PIAS3 (show PIAS3 ELISA Kits) levels are reduced in medulloblastomas in vivo and in vitro, of which PIAS3 (show PIAS3 ELISA Kits) downregulation is more reversely correlated with STAT3 (show STAT3 ELISA Kits) activation. In resveratrol-suppressed medulloblastoma cells with STAT3 (show STAT3 ELISA Kits) downregulation and decreased incidence of STAT3 (show STAT3 ELISA Kits) nuclear translocation, PIAS3 (show PIAS3 ELISA Kits) is upregulated, the SHP2 level remains unchanged and SOCS3 (show SOCS3 ELISA Kits) is downregulated.
SHP2-ERK2 (show MAPK1 ELISA Kits) signaling acts upstream of C/EBPalpha (show CEBPA ELISA Kits) as a regulator of cell surface I antigen synthesis.
could promote hepatocellular carcinoma cell dedifferentiation and liver cancer stem cell expansion by amplifying beta-catenin (show CTNNB1 ELISA Kits) signaling
SHP2 supports basal pulmonary endothelial barrier function by coordinating the tyrosine phosphorylation profile of VE-cadherin (show CDH5 ELISA Kits), beta-catenin (show CTNNB1 ELISA Kits), and p190RhoGAP (show GRLF1 ELISA Kits) and the activity of RhoA (show RHOA ELISA Kits).
Ptpn11 gain-of-function mutations are associated with myeloproliferative neoplasm.
aberrant SHP2 signaling during cardiac development leads to congenital heart disease and adult-onset heart hypertrophy
Data suggest that phosphorylation of Shp2/Ptpn11 at Tyr542 and its translocation to postsynaptic compartment are integral processes in synaptic scaling/homeostasis; Shp2 phosphatase activity is critical to regulation of Ser (show SIGLEC1 ELISA Kits)(P)845 GluA1 (show GRIA1 ELISA Kits) and surface expression of GluA1 (show GRIA1 ELISA Kits) during synaptic scaling. (Shp2/Ptpn11 = protein tyrosine phosphatase non-receptor type 11; GluA1 (show GRIA1 ELISA Kits) = glutamate receptor ionotropic Ampa1 (show GRIA1 ELISA Kits) [alpha 1])
data suggested that deletion of Shp2 impaired IL-25 (show IL25 ELISA Kits) production in bronchial epithelial cells in vitro, but might yet have minor influence on OVA-induced allergic reaction in vivo
The effects of SHP2 overexpression and inhibition on fibroblast response to profibrotic stimuli were analyzed in in the bleomycin model of lung fibrosis by SHP2-lentiviral administration in transgenic mice carrying a constitutively active SHP2 mutation. Mice carrying the Noonan syndrome-associated SHP2 mutation were resistant bleomycin induced pulmonary fibrosis.
Data show aberrant neuronal activity-induced signaling and regulation of gene expression in protein tyrosine phosphatase (show ACP1 ELISA Kits), non-receptor type 11 (Ptpn11D61Y) mutation and suggest that these deficits contribute to the pathophysiology of cognitive impairments in Noonan syndrome (NS).
This study indicates that Shp2 is required to orchestrate macrophage function and regulate host innate immunity against pulmonary bacterial infection.
In conclusion, our data suggest that SIRPalpha signaling through SHP-2-PI3K-Akt2 (show AKT2 ELISA Kits) strongly influences osteoblast differentiation from bone marrow stromal cells.
SHP-2 is functionally important for the maintenance of appropriate barrier function and host-microbiota homeostasis in the large intestine.
This study reveals the critical contribution of Ptpn11 mutations in the bone marrow microenvironment to leukaemogenesis and identifies CCL3 (show CCL3 ELISA Kits) as a potential therapeutic target for controlling leukaemic progression in Noonan syndrome and for improving stem cell transplantation therapy in Noonan-syndrome-associated leukaemias.
The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP contains two tandem Src homology-2 domains, which function as phospho-tyrosine binding domains and mediate the interaction of this PTP with its substrates. This PTP is widely expressed in most tissues and plays a regulatory role in various cell signaling events that are important for a diversity of cell functions, such as mitogenic activation, metabolic control, transcription regulation, and cell migration. Mutations in this gene are a cause of Noonan syndrome as well as acute myeloid leukemia. Two transcript variants encoding different isoforms have been found for this gene.
, protein-tyrosine phosphatase 1D
, protein-tyrosine phosphatase 2C
, tyrosine-protein phosphatase non-receptor type 11
, SH2 domain-containing protein tyrosine phosphatase-2
, protein-tyrosine phosphatase SYP
, SH-PTP2 protein tyrosine phosphatase non-receptor type 11
, SH-PTP2 protein tyrosine phosphatase, non-receptor type 11
, encodes catalytic domain
, protein tyrosine phosphatase SH-PTP2
, protein tyrosine phosphatase, non-receptor type 11 (Noonan syndrome 1)
, non-receptor type protein tyrosine phosphatase SHP2